Genzyme Institutes Further Rationing Of Cerezyme, Fabrazyme To Build Inventory
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite last year's manufacturing problems and the resulting shortages, biotech says 85 percent of U.S. Cerezyme patients have returned.
You may also be interested in...
Differentiation Will Be Key Challenge For Shire's Gaucher Disease Drug Vpriv
The FDA approval of Shire's Vpriv (velaglucerase) means that Genzyme's Cerezyme (imiglucerase) finally has competition in the Gaucher disease space. But market analysts are strongly divided on whether velaglucerase or a pending Pfizer/Protalix drug will be better positioned to make a dent in Cerezyme's market share
Differentiation Will Be Key Challenge For Shire's Gaucher Disease Drug Vpriv
The FDA approval of Shire's Vpriv (velaglucerase) means that Genzyme's Cerezyme (imiglucerase) finally has competition in the Gaucher disease space. But market analysts are strongly divided on whether velaglucerase or a pending Pfizer/Protalix drug will be better positioned to make a dent in Cerezyme's market share
Varied Outcomes Predicted On Icahn's Bid For Four Seats On Genzyme's Board
Activist investor Carl Icahn seeking the kind of gains similar to those he realized at Biogen Idec.